Denali Therapeutics (NASDAQ:DNLI – Get Free Report) released its earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.09, Briefing.com reports. The firm had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $10.00 million. During the same period last year, the business earned $1.30 earnings per share. The business’s revenue was down 99.7% on a year-over-year basis.
Denali Therapeutics Trading Down 6.3 %
DNLI stock traded down $1.46 during trading on Friday, hitting $21.87. The company had a trading volume of 1,478,454 shares, compared to its average volume of 1,029,904. Denali Therapeutics has a one year low of $14.56 and a one year high of $28.31. The business has a 50-day moving average of $21.85 and a 200-day moving average of $19.61. The stock has a market cap of $3.12 billion, a PE ratio of -22.78 and a beta of 1.40.
Insider Buying and Selling at Denali Therapeutics
In related news, Director Jennifer E. Cook sold 1,458 shares of the stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $21.73, for a total value of $31,682.34. Following the completion of the sale, the director now directly owns 20,038 shares of the company’s stock, valued at approximately $435,425.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $22.12, for a total transaction of $663,600.00. Following the completion of the sale, the director now owns 34,404 shares in the company, valued at approximately $761,016.48. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jennifer E. Cook sold 1,458 shares of Denali Therapeutics stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $21.73, for a total value of $31,682.34. Following the sale, the director now owns 20,038 shares of the company’s stock, valued at approximately $435,425.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,146 shares of company stock valued at $710,274. 7.90% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on Denali Therapeutics
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Further Reading
- Five stocks we like better than Denali Therapeutics
- What is a SEC Filing?
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What Are Trending Stocks? Trending Stocks Explained
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- 3 Best Fintech Stocks for a Portfolio Boost
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.